Novo Nordisk signed a licensing deal with Jiangsu Hengrui Pharmaceuticals for HRS-1596, a preclinical once-weekly oral dual GLP-1/GIP receptor agonist. Novo will pay $300 million upfront, with total potential deal value up to $2.6 billion tied to development, regulatory and commercial milestones. The agreement gives Novo rights outside China, Taiwan and nearby territories, while positioning the company to compete with other next-gen obesity programs that aim to improve convenience and tolerability beyond daily dosing. HRS-1596 was described as “Phase 1 ready,” but remains preclinical, keeping timelines uncertain. Novo’s recent activity in obesity includes multiple external sourcing and pipeline rebuild efforts as the category faces evolving competitive pressures and concerns about future pricing dynamics. Hengrui has been an active source of obesity innovation for global partners. For the market, the deal reinforces that weekly oral dosing is now treated as a central differentiator in obesity strategy, not just a convenience feature.